Association between cytokine production and disease severity in Alzheimer's Disease

Iranian Journal of Allergy, Asthma and Immunology

Volumn 13, Issue 6, 2014, Pages 433-439

  Azad, Farahzad Jabbari ^a   Talaei, Ali ^b   Rafatpanah, Houshang ^a   Yousefzadeh, Hadis ^c   Jafari, Rahele ^b   Jafari, Majid ^a   Talaei, Andisheh ^d   Hosseini, Reza Farid ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d UNIVERSITY OF TEHRAN   (Iran)

Author keywords

Alzheimer's Disease (AD); Cytokine; Vitamin B12

Indexed keywords

CYANOCOBALAMIN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 4; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; CYTOKINE;

AGE; AGED; ALZHEIMER DISEASE; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL LEVEL; CLINICAL ARTICLE; CLINICAL DEMENTIA RATIO; COGNITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOBAL DETERIORATION SCALE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; HUMAN CELL; LYMPHOCYTE CULTURE; MALE; MENTAL PERFORMANCE; MINI MENTAL STATE EXAMINATION; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT RISK; T LYMPHOCYTE; VITAMIN BLOOD LEVEL; BIOSYNTHESIS; CASE CONTROL STUDY; IMMUNOLOGY; SEVERITY OF ILLNESS INDEX;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; CYTOKINES; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 84907717429     PISSN: 17351502     EISSN: 17355249     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Shabestari M, Jabbari F, Hosseni RF, Rezaee SR, Gharivani Y, Valizadeh N, et al. Human T Lymphotropic Virus Type I (HTLV-I) is a Risk Factor for Coronary Artery Disease. Iran J Basic Med Sci; Vol 2013; 16(3):224-7.
2. Hosseini RF, Azad FJ, Talaee A, Miri S, Mokhber N, Hosseini FF, et al. Assessment of the immune system activity in Iranian patients with Major Depression Disorder (MDD). Iran J Immunol 2007; 4(1):38-43
3. Zilka N, Ferencik M, Hulin I. Neuroinflammation in Alzheimer's disease: protector or promoter? Bratisl Lek Listy 2006; 107(9-10):374-83.
4. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21(3):383-421.
5. Tuppo EE, Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37(2):289-305.
6. Griffin W, Stanley L, Ling C, White L, MacLeod V, Perrot L, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 1989; 86(19):7611-5.
7. Jones S, Small B, Fratiglioni L, Backman L. Predictors of cognitive change from preclinical to clinical Alzheimer's disease. Brain Cogn 2002; 49(2):210-3.
8. Hull M, Strauss S, Berger M, Volk B, Bauer J. Inflammatory mechanisms in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1996; 246(3):124-8.
9. Flanders KC, Ren RF, Lippa CF. Transforming growth factor-betas in neurodegenerative disease. Prog Neurobiol 1998; 54(1):71-85.
10. Breitner JC. Inflammatory processes and antiinflammatory drugs in Alzheimer's disease: a current appraisal. Neurobiol Aging 1996; 17(5):789-94.
11. Tarkowski E. Cytokines in dementias. Curr Drug Targets Inflamm Allergy 2002; 1(2):193-200.
12. Bauer J, Strauss S, Schreiter-Gasser U, Ganter U, Schlegel P, Witt I, et al. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS lett 1991; 285(1):111-4.
13. van der Wal EA, Gómez-Pinilla F, Cotman CW. Transforming growth factor-[beta] 1 is in plaques in Alzheimer and Down pathologies. Neuroreport 1993; 4(1):69-72.
14. Yamada T, Horisberger M, Kawaguchi N, Moroo I, Toyoda T. Immunohistochemistry using antibodies to α- interferon and its induced protein, MxA, in Alzheimer's and Parkinson's disease brain tissues. Neurosci Lett 1994; 181(1-2):61-4.
15. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 1994;61 (4):745-54.
16. Bunout D, Barrera G, Hirsch S, Gattas V, de la Maza MP, Haschke F, et al. Effects of a nutritional supplement on the immune response and cytokine production in freeliving Chilean elderly. JPEN J Parenter Enteral Nutr 2004; 28(5):348-54.
17. Scalabrino G, Carpo M, Bamonti F, Pizzinelli S, D'Avino C, Bresolin N, et al. High tumor necrosis factor-α in levels in cerebrospinal fluid of cobalamin-deficient patients. Ann Neurol 2004; 56(6):886-90.
18. Yamashiki M, Nishimura A, Kosaka Y. Effects of methylcobalamin (vitamin B12) on in vitro cytokine production of peripheral blood mononuclear cells. J Clin Lab Immunol 1992; 37(4):173-82.
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington. DC.: American Psychiatric Association; 2000.
20. Vasto S, Candore G, Listì F, Balistreri CR, Colonna-Romano G, Malavolta M, et al. Inflammation, genes and zinc in Alzheimer's disease. Brain Res Rev 2008; 58(1):96-105.
21. Britschgi M, Wyss-Coray T. Systemic and acquired immune responses in Alzheimer's disease. Int Rev Neurobiol 2007; 82:205-33.
22. Mrak RE, Griffin WS. Potential inflammatory biomarkers in Alzheimer's disease. J Alzheimers Dis 2005; 8(4):369-75.
23. Politis A, Olgiati P, Malitas P, Albani D, Signorini A, Polito L, et al. Vitamin B12 levels in Alzheimer's disease: association with clinical features and cytokine production. J Alzheimers Dis 2010; 19(2):481-8.
24. Li Y, Liu L, Kang J, Sheng JG, Barger SW, Mrak RE, et al. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. J Neurosci 2000; 20(1):149-55.
25. Sheng JG, Jones RA, Zhou XQ, McGinness JM, Van Eldik LJ, Mrak RE, et al. Interleukin-1 promotion of MAPK-p38 overexpression in experimental animals and in Alzheimer's disease: potential significance for tau protein phosphorylation. Neurochem Int 2001; 39(5-6):341-8.
26. Sheng J, Zhu S, Jones R, Griffin W, Mrak R. Interleukin- 1 Promotes Expression and Phosphorylation of Neurofilament and tau Proteins in Vivo. Exp Neuro 2000; 163(2):388-91.
27. Griffin WST, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution. J Neuropathol Exp Neurol 1995; 54(2):276-81.
28. Mehlhorn G, Hollborn M, Schliebs R. Induction of cytokines in glial cells surrounding cortical beta-amyloid plaques in transgenic Tg2576 mice with Alzheimer pathology. Int J Dev Neurosci 2000; 18(4-5):423-31.
29. Luterman JD, Haroutunian V, Yemul S, Ho L, Purohit D, Aisen PS, et al. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Arch Neurol 2000; 57(8):1153-60.
30. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, et al. Cytokine indices in Alzheimer's temporal cortex: no changes in mature IL-1 beta or IL- 1RA but increases in the associated acute phase proteins IL-6, alpha 2-macroglobulin and C-reactive protein. Brain Res 1993; 629(2):245-52.
31. Araujo DM, Lapchak PA. Induction of immune system mediators in the hippocampal formation in Alzheimer's and Parkinson's diseases: selective effects on specific interleukins and interleukin receptors. Neuroscience 1994; 61(4):745-54.
32. Marti{dotless} nez M, Fernández-Vivancos E, Frank A, De la Fuente M, Hernanz A. Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease: relationship with IL-6 concentrations. Brain Res 2000; 869(1):216-9.
33. Blum-Degena D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202(1):17-20.
34. März P, Heese K, Hock C, Golombowski S, Müller-Spahn F, Rose-John S, et al. Interleukin-6 (IL-6) and soluble forms of IL-6 receptors are not altered in cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett 1997; 239(1):29-32.
35. Rainero I, Bo M, Ferrero M, Valfre W, Vaula G, Pinessi L. Association between the interleukin-1alpha gene and Alzheimer's disease: a meta-analysis. Neurobiol Aging 2004; 25(10):1293-8.
36. Lee KS, Chung JH, Choi TK, Suh SY, Oh BH, Hong CH. Peripheral cytokines and chemokines in Alzheimer's disease. Dement Geriatr Cogn Disord 2009; 28(4):281-7.
37. Chao C, Ala T, Hu S, Crossley K, Sherman R, Peterson P, et al. Serum cytokine levels in patients with Alzheimer's disease. Clin Diagn Lab Immunol 1994; 1(4):433-6.
38. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 2005; 29(3):381-93.
39. Chao CC, Molitor TW, Hu S. Neuroprotective role of IL- 4 against activated microglia. J Immunol 1993; 151(3):1473-81.